Chinese Japanese Germany Korea
ChemicalBook >> CAS DataBase List >>ABT-263

ABT-263

ABT-263 Structure
ABT-263 structure
CAS No.
923564-51-6
Chemical Name:
ABT-263
Synonyms
Navitoclax;ABT 263;CS-1871;CS-1967;Navitoclax (ABT-263);Navitoclax-D8;ABT263;ABT-263;Navitoclax, >=98%;ABT 263 USP/EP/BP;ABT-263,Navitoclax
CBNumber:
CB21872884
Molecular Formula:
C47H55ClF3N5O6S3
Molecular Weight:
974.62
MDL Number:
MFCD12756219
MOL File:
923564-51-6.mol
MSDS File:
SDS
TDS File:
TDS
Last updated:2026-08-20 20:20:01
Request For Quotation

ABT-263 Properties

Melting point 114-116°C
Density 1.41±0.1 g/cm3(Predicted)
storage temp. -20°C Freezer, Under Inert Atmosphere
solubility Soluble in DMSO (up to 25 mg/ml).
form solid
pka 4.60±0.10(Predicted)
color White
Stability Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
InChIKey JLYAXFNOILIKPP-KXQOOQHDSA-N
SMILES C(NS(C1=CC=C(N[C@@H](CSC2=CC=CC=C2)CCN2CCOCC2)C(S(C(F)(F)F)(=O)=O)=C1)(=O)=O)(=O)C1=CC=C(N2CCN(CC3CC(C)(C)CCC=3C3=CC=C(Cl)C=C3)CC2)C=C1
CAS DataBase Reference 923564-51-6
NCI Dictionary of Cancer Terms ABT-263; navitoclax
FDA UNII XKJ5VVK2WD
NCI Drug Dictionary navitoclax

SAFETY

Risk and Safety Statements

Symbol(GHS)  Exclamation Mark (GHS07)
GHS07
Signal word  Warning
Hazard statements  H303-H320
Precautionary statements  P312-P264-P305+P351+P338-P337+P313
HS Code  29339900

ABT-263 price More Price(72)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 11500 ABT-263 ≥98% 923564-51-6 1mg $29 2026-04-30 Buy
Cayman Chemical 11500 ABT-263 ≥98% 923564-51-6 5mg $65 2026-04-30 Buy
Cayman Chemical 11500 ABT-263 ≥98% 923564-51-6 10mg $115 2026-04-30 Buy
Cayman Chemical 11500 ABT-263 ≥98% 923564-51-6 25mg $215 2026-04-30 Buy
TRC TRC-A112500-5MG ABT 263 923564-51-6 5mg $59 2026-06-03 Buy
Product number Packaging Price Buy
11500 1mg $29 Buy
11500 5mg $65 Buy
11500 10mg $115 Buy
11500 25mg $215 Buy
TRC-A112500-5MG 5mg $59 Buy

ABT-263 Chemical Properties, Uses, Production

Description

ABT-263 (923564-51-6) is a potent and selective Bcl-2 family inhibitor / BH3 domain mimetic which binds to Bcl-2, Bcl-xLand Bcl-w (Ki<1 nM). A useful tool compound which has shown interesting results in various cancer clinical trials.2Synergizes with deoxyglucose and other agents, inducing apoptosis in cancer cells in a xenograft mouse model.3A novel senolytic agent, inducing apoptosis preferentially in senescent cells in a cell type-restricted manner.4

Chemical Properties

Pale Yellow Solid

Uses

ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤ 1 nM, respectively.

Uses

A novel inhibitor of antiapoptotic BCL-2 proteins; a new promising anticancer drug candidate.

Definition

ChEBI: Navitoclax is a N-sulfonylcarboxamide resulting from the formal condensation of the carboxy group of 4-{4-[(4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro[biphenyl]-2-yl)methyl]piperazin-1-yl}benzoic acid with the amino group of 4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide. It is a BH3-mimetic drug which targets the anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, including BCL-2, BCL-xL, and BCL-w, and induces apoptosis in cancer cells. Currently under clinical investigation as treatment for solid tumors and hematologic malignancies. It has a role as a B-cell lymphoma 2 inhibitor, an apoptosis inducer and an antineoplastic agent. It is a member of piperazines, a member of monochlorobenzenes, a member of morpholines, an aryl sulfide, a N-sulfonylcarboxamide, a sulfone, an organofluorine compound, a secondary amino compound and a tertiary amino compound.

Mechanism of action

ABT‐263 exerts its senolytic activity in senescent tumor cells by inhibiting BCL‐XL's interaction with BAX. ABT‐263 is a BH3 mimetic that inhibits anti‐apoptotic BCL‐2 family proteins by impeding their ability to bind pro‐apoptotic proteins, such as BAK and BAX. BCL‐2 and BCL‐XL are the primary targets of ABT‐263 in cancer cells. 

Pharmacokinetics

The pharmacokinetic profile of ABT-263 is characterized by low plasma clearance values and low volumes of distribution in mice, rats, dogs, and monkeys, with plasma elimination half-lives after i.v. Dose of 4.6 to 8.4 hours. Bioavailability after oral gavage was ～20% in all four species. Due to its low aqueous solubility, ABT-263 displays a prolonged dissolution rate-limited oral absorption. P.o. administration in lipid-based formulations, in which the compound is significantly more soluble, yields enhanced absorption with bioavailability near 50% and an oral elimination half-life of 8.9 hours in dogs[5].

in vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263.

storage

Store at -20°C

Background

ABT-263 is a potent and orally bioavailable Bcl-2 family inhibitor. This small molecule mimetic of BH3 domains specifically binds to Bcl-2, Bcl-xL, and Bcl-W with a Ki value of less than 1 nM. ABT-263 has been shown to have antitumor effects on small cell lung cancer xenograft models, resulting in complete tumor regression in some cases. Studies have shown that ABT-263 can enhance the effectiveness of chemotherapeutic and targeted agents against solid tumors. ABT-263 induces apoptosis, particularly in certain types of senescent cells.

References

[1] Tse et al. (2008), ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor; Cancer Res., 68: 3421.
[2] Vogler et al. (2009), Bcl-2 inhibitors: small molecules with a big impact on cancer therapy; Cell Death Differ., 16: 360.
[3] Yamaguchi et al. (2011), Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy; PLoS ONE, 6(9): e24102.
[4] Zhu et al. (2016), Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors; Aging Cell, 15: 428.
[5] Tse et al. (2023), Data from ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor.

ABT-263 Preparation Products And Raw materials

Raw materials

Preparation Products

ABT-263 Suppliers

Global Suppliers ( 293)
Supplier Tel Email Country ProdList Advantage
Lanzhou HuaHao Pharmaceutical Co., Ltd. 18189674620 761137152@qq.com China 490 55
Guangzhou Isun Pharmaceutical Co., Ltd 020-39119399 18927568969 isunpharm@qq.com China 4773 55
Zhengzhou HSH Science & Technology Co., Ltd. 0371-55932928 18937192232; 1282296214@qq.com China 497 55
Hunan Huayi Zhide Pharmaceutical Technology Co., Ltd. 17752881701 190060276@qq.com China 199 58
Shanghai Chaolan Chemical Technology Center QQ：65489617 13301690235 Sales@ATKchemical.com China 9699 58
Shanghai Aladdin Biochemical Technology Co.,Ltd. 6206333 13167063860 anhua.mao@aladdin-e.com China 43486 58
Shanghai Fine Biotech Co.，Ltd 18221172427; 18221172427 sale@fine-biotech.com China 227 58
Shanghai Zhuyan Biotechnology Co., Ltd. 17521259211 17521259211@163.com China 136 58
Shanghai Boyle Chemical Co., Ltd. sales@boylechem.com China 2915 55
J & K SCIENTIFIC LTD. 18210857532 18210857532 jkinfo@jkchemical.com China 96815 76
Supplier Advantage
Lanzhou HuaHao Pharmaceutical Co., Ltd. 55
Guangzhou Isun Pharmaceutical Co., Ltd 55
Zhengzhou HSH Science & Technology Co., Ltd. 55
Hunan Huayi Zhide Pharmaceutical Technology Co., Ltd. 58
Shanghai Chaolan Chemical Technology Center 58
Shanghai Aladdin Biochemical Technology Co.,Ltd. 58
Shanghai Fine Biotech Co.，Ltd 58
Shanghai Zhuyan Biotechnology Co., Ltd. 58
Shanghai Boyle Chemical Co., Ltd. 55
J & K SCIENTIFIC LTD. 76

Related articles

  • ABT-263
  • Navitoclax, also known as ABT-263 and ABT 263, is a potent, oral biologically active inhibitor of the Bcl-2 protein family, ac....
  • Oct 28,2021

View Latest Price from ABT-263 manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Navitoclax pictures 2026-08-20 Navitoclax
923564-51-6
 $39.00-84.00 98.88% 10g TargetMol Chemicals Inc.
ABT 263 pictures 2019-07-06 ABT 263
923564-51-6
 $2.00 1KG 99% Career Henan Chemical Co
  • Navitoclax pictures
  • Navitoclax
    923564-51-6
  • $39.00-84.00
  • 98.88%
  • TargetMol Chemicals Inc.
  • ABT 263 pictures
  • ABT 263
    923564-51-6
  • $2.00
  • 99%
  • Career Henan Chemical Co

ABT-263 Spectrum

ABT-263(923564-51-6)1HNMR

923564-51-6 (ABT-263) Related Search:

Cl 82198 hydrochloride Acetylcholine PLX4032 Y-27632 dihydrochloride LFM-A13
TCPOBOP Adapalene ABT-888 Ribonucleic acid ABT-199
ABT 737 MG-132 Olaparib

1of3

ABT263;ABT-263 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide (R)-4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(4-(4-morpholino-1-(phenylthio)butan-2-ylamino)-3-(trifluoromethylsulfonyl)phenylsulfonyl)benzamide NAVITOCLAX;ABT 263;ABT263 (R)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide 4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide BenzaMide, 4-(4-((2-(4-chlorophenyl)-5,5-diMe Navitoclax (ABT-263) Benzamide, 4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-N-((4-(((1R)-3-(4-morpholinyl)-1-((phenylthio)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)- ABT-263,Navitoclax (S)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide 4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide ABT-26 ABT 263 4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide Navitoclax, >=98% (S)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperaz (R)-4-(4-((2-(4-Chlorophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(4-(4-morph ABT 263, 98%, potent inhibitor of Bcl-xL,Bcl-2 and Bcl-w (R)-4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[3-morpholino-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide ABT 263 USP/EP/BP Navitoclax-D8 ABT-263(Navitoclax)/ABT263 ABT-263, Bcl-2 family protein inhibitor Navitoclax, 10 mM in DMSO Navitoclax (ABT-263) ，S1001 ABT 263 CS-1871 CS-1967 Navitoclax 923564-51-6 23564-51-6 C47H55ClF3N5O6S3 Inhibitor Apis Chiral Reagents Inhibitors Intermediates & Fine Chemicals Pharmaceuticals Sulfur & Selenium Compounds